CRVO Latest Press Releases

-- November 9, 2026 --

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- October 29, 2026 --

CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) Globe Newswire 7:30 AM

-- October 12, 2026 --

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 Globe Newswire 7:30 AM

-- September 28, 2026 --

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit Globe Newswire 7:30 AM

-- September 22, 2026 --

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference Globe Newswire 7:30 AM

-- September 10, 2026 --

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 Globe Newswire 7:30 AM

-- September 8, 2026 --

CervoMed to Participate in September Investor Conferences Globe Newswire 7:30 AM

-- August 10, 2026 --

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- August 5, 2026 --

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 7:30 AM

-- August 4, 2026 --

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) Globe Newswire 5:15 AM

-- July 14, 2026 --

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) Globe Newswire 7:30 AM

-- July 9, 2026 --

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia Globe Newswire 7:30 AM

-- July 6, 2026 --

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 Globe Newswire 7:30 AM

-- June 22, 2026 --

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Globe Newswire 4:05 PM

-- June 18, 2026 --

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Globe Newswire 12:35 PM

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 Globe Newswire 7:00 AM

-- June 16, 2026 --

Wall Street Chases the Next Big Breakout Globe Newswire 3:22 PM

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum Globe Newswire 10:18 AM

-- June 12, 2026 --

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit Globe Newswire 7:30 AM

-- June 10, 2026 --

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes